Version 1
: Received: 26 September 2024 / Approved: 27 September 2024 / Online: 27 September 2024 (13:38:33 CEST)
How to cite:
Pisotskyi, O.; Petrasz, P.; Zorga, P.; Gałęski, M.; Szponar, P.; Brzeźniakiewicz-Janus, K.; Drewa, T.; Kaczmarek, K.; Czarnogórski, M. C.; Adamowicz, J. Enhancing Prostate Cancer Staging: Association of 68Ga-PSMA PET/CT Imaging with Histopathological Grading in Treatment-Naive Patients. Preprints2024, 2024092221. https://doi.org/10.20944/preprints202409.2221.v1
Pisotskyi, O.; Petrasz, P.; Zorga, P.; Gałęski, M.; Szponar, P.; Brzeźniakiewicz-Janus, K.; Drewa, T.; Kaczmarek, K.; Czarnogórski, M. C.; Adamowicz, J. Enhancing Prostate Cancer Staging: Association of 68Ga-PSMA PET/CT Imaging with Histopathological Grading in Treatment-Naive Patients. Preprints 2024, 2024092221. https://doi.org/10.20944/preprints202409.2221.v1
Pisotskyi, O.; Petrasz, P.; Zorga, P.; Gałęski, M.; Szponar, P.; Brzeźniakiewicz-Janus, K.; Drewa, T.; Kaczmarek, K.; Czarnogórski, M. C.; Adamowicz, J. Enhancing Prostate Cancer Staging: Association of 68Ga-PSMA PET/CT Imaging with Histopathological Grading in Treatment-Naive Patients. Preprints2024, 2024092221. https://doi.org/10.20944/preprints202409.2221.v1
APA Style
Pisotskyi, O., Petrasz, P., Zorga, P., Gałęski, M., Szponar, P., Brzeźniakiewicz-Janus, K., Drewa, T., Kaczmarek, K., Czarnogórski, M. C., & Adamowicz, J. (2024). Enhancing Prostate Cancer Staging: Association of 68Ga-PSMA PET/CT Imaging with Histopathological Grading in Treatment-Naive Patients. Preprints. https://doi.org/10.20944/preprints202409.2221.v1
Chicago/Turabian Style
Pisotskyi, O., Michał Cezary Czarnogórski and Jan Adamowicz. 2024 "Enhancing Prostate Cancer Staging: Association of 68Ga-PSMA PET/CT Imaging with Histopathological Grading in Treatment-Naive Patients" Preprints. https://doi.org/10.20944/preprints202409.2221.v1
Abstract
Objective: The study aims to evaluate the correlation between 68Ga-PSMA uptake in PSMA PET/CT in primary prostate cancer (PC) and its histopathological grading (Gleason Score and ISUP grade). Additionally, we compared preoperative biopsy histopathological findings with definitive pathology results in radical prostatectomy (RP) specimens.
Methods: We retrospectively analyzed 86 patients who underwent 68Ga-PSMA PET/CT for primary PC staging, of which 40 patients later underwent radical prostatectomy. PET/CT results, including SUVmax values, were correlated with GS and PSA concentrations. Histopathology reports were analyzed and compared between biopsy and final pathology results following RP.
Results: A significant positive correlation was observed between SUVmax and ISUP grades (Pearson's ρ = 0.34, p < 0.001), with higher SUVmax values associated with more advanced grades. A cut-off SUVmax value of 5.64 was determined to predict upstaging in patients, yielding a sensitivity of 76% and a specificity of 60% (AUC = 0.82, 95% CI: 0.70–0.94). Additionally, 57.5% of patients experienced a grade shift following RP, with a 35% upgrade and 22.5% downgrade in ISUP grades.
Conclusion: 68Ga-PSMA PET/CT demonstrated high sensitivity in detecting high-risk prostate cancer, particularly in patients with GS > 7 or PSA levels ≥ 10 ng/ml. The findings suggest that this imaging modality may be less effective for staging of patients with lower GS or PSA values, that is low-risk PCa. Further prospective studies are necessary to validate these results.
Keywords
68Ga-PSMA PET/CT; Prostate Cancer Staging; Histopathological Grading; SUVmax Correlation; Biopsy vs. Final Pathology; PSMA Expression
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
